Hims & Hers Plans to Expand Access to FDA-Approved GLP-1 Weight Loss Drugs via Novo Nordisk Collaboration, Limit Compounded Semaglutide and Transition Eligible Patients

Reuters03-12
Hims & Hers Plans to Expand Access to FDA-Approved GLP-1 Weight Loss Drugs via <a href="https://laohu8.com/S/NVO">Novo Nordisk</a> Collaboration, Limit Compounded Semaglutide and Transition Eligible Patients

Hims & Hers Health Inc. plans to align its U.S. weight loss strategy with its global model by expanding access to a broader assortment of FDA-approved GLP-1 medications and limiting compounded semaglutide availability. The company will stop advertising compounded GLP-1 offerings and aims to transition existing patients to FDA-approved options when clinically appropriate. Under a new agreement with Novo Nordisk, Hims & Hers expects to add Ozempic and Wegovy injections and tablets to its platform later this month and will educate customers on expanded treatment choices while continuing to provide support services such as provider access, nutrition guidance, and ongoing clinical check-ins.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001773751-26-000033), on March 11, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment